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Impact of Cardiac Contractility Modulation
on Left Ventricular Global and Regional
Function and Remodeling
Cheuk-Man Yu, MD,* Joseph Yat-Sun Chan, MB,* Qing Zhang, MM, PHD,*
Gabriel W. K. Yip, MD,* Yat-Yin Lam, MB,* Anna Chan, MB,*
Daniel Burkhoff, MD, PHD,†‡ Pui-Wai Lee, MB,* Jeffrey Wing-Hong Fung, MD*
Hong Kong, China; and New York and Orangeburg, New York
O B J E C T I V E S This study aimed to evaluate the impact of cardiac contractility modulation (CCM) on
left ventricular (LV) size and myocardial function.
B A C KG ROUND CCM is a device-based therapy for patients with advanced heart failure. Previous
studies showed that CCM improved symptoms and exercise capacity; however, comprehensive
assessment of LV structure, function, and reverse remodeling is not available.
METHOD S Thirty patients (60  11 years, 80% male) with New York Heart Association (NYHA)
functional class III heart failure, ejection fraction35%, and QRS120 ms were assessed at baseline and
3 months. LV reverse remodeling was measured by real-time 3-dimensional echocardiography. Using
tissue Doppler imaging, the peak systolic velocity (Sm) and peak early diastolic velocity (Em) were
calculated for LV function, while the standard deviation of the time to peak systolic velocity (Ts-SD) and
the time to peak early diastolic velocity (Te-SD) were calculated for mechanical dyssynchrony.
R E S U L T S LV reverse remodeling was evident, with a reduction in LV end-systolic volume by
11.5  10.5% and a gain in ejection fraction by 4.8  3.6% (both p  0.001). Myocardial contraction
was improved in all LV walls, including sites remote from CCM delivery (all p  0.05); hence, the mean
Sm of 12 (2.2  0.6 cm/s vs. 2.5  0.7 cm/s) or 6 basal LV segments (2.5  0.6 cm/s vs. 3.0  0.7 cm/s)
were increased signiﬁcantly (both p  0.001). In contrast, CCM had no impact on regional or global Em
(2.9  1.3 cm/s vs. 2.9  1.1 cm/s), whereas Ts-SD (28.2  11.2 ms vs. 27.9  12.7 ms) and Te-SD (30.0
 18.3 ms vs. 30.1  20.7 ms) remained unchanged (all p  NS). Mitral regurgitation was reduced (22
 14% vs. 17  15%, p  0.02). Clinically, there was improvement of NYHA functional class (p  0.001)
and 6-min hall walk distance (p  0.015). A 24-h Holter monitor showed that premature ventricular
contractions were not increased during CCM.
CONC L U S I O N S CCM improves both global and regional LV contractility, including regions remote
from the impulse delivery, and may contribute to LV reverse remodeling and gain in systolic function.
Such improvement is unrelated to diastolic function or mechanical dyssynchrony. (J Am Coll Cardiol
Img 2009;2:1341–9) © 2009 by the American College of Cardiology Foundation
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1342any patients with advanced heart failure
(HF) are refractory to optimal standard
medical therapy. This has given rise to
development and testing of a host of new
evice-based therapies (1). One more recent and
otentially broadly applicable treatment under inves-
igation is cardiac contractility modulation (CCM)
lectrical signals (2,3). CCM signals are relatively
igh-voltage electrical impulses applied to the myo-
ardium during the absolute refractory period. These
ignals do not initiate a new contraction or modify
ctivation sequence as is the case with other therapies
uch as cardiac resynchronization therapy (CRT) (4).
ather, CCM signals are intended to enhance systolic
unction of the failing myocardium (5–8). Results of
ecent clinical studies suggest that CCM therapy is
afe and improves exercise tolerance and quality of life in
patients with HF (3,9–11) without increasing
myocardial oxygen consumption (12). Recent
studies in animal models and patients with
HF indicate that a novel mechanism under-
lying these effects is normalized expression
of genes known to be pathologically up- or
down-regulated in HF (8,13).
Despite consistent findings concerning
effects on exercise tolerance and quality of
life, findings have been inconsistent with
regard to the effect of CCM on left ventric-
ular (LV) structure and function (10,11).
Use of 2-dimensional (2D) echocardiogra-
phy for such assessments is associated with
significant variability, especially in the con-
text of multicenter studies, even when a core
laboratory is used. In contrast, real-time
3-dimensional (3D) echocardiography offers
the opportunity for significantly more accu-
rate and reproducible assessments, and re-
uces the need for large sample size (14). Further-
ore, the potential mechanisms of how CCM may
ffect LV function have not been evaluated in previous
tudies. In particular, whether CCM would enhance
nly septal function where the 2 electrodes are im-
lanted, or whether they impact LV free-wall function
nd the synchrony of mechanical contraction, are
nknown. Therefore, the purpose of this study was to
est the impact of CCM on LV size and global and
egional myocardial function by real-time 3D echo-
ardiography and tissue Doppler imaging.
E T H O D S
atients and study protocol. The present study en-
tion
g
aire
of
of
cityolled 30 consecutive patients (mean age 60  11 tears, 80% male) who received CCM treatment
ith an Optimizer III System (IMPULSE Dynam-
cs, Inc., Orangeburg, New York). Patients were
ncluded if they had an ejection fraction 35%,
ew York Heart Association (NYHA) functional
lass III who remained symptomatic despite opti-
al medical therapy, and not eligible for CRT. The
ajor exclusion criteria included permanent or
ersistent atrial fibrillation, peak VO2 9 ml/kg/
in, patients who had an aortic or tricuspid me-
hanical prosthetic valve, patients with QRS dura-
ion 120 ms, hospitalization within 1 month for
cute exacerbation of HF, revascularization within
month, or acute myocardial infarction within 3
onths of study entry.
Baseline testing included echocardiography with
eal-time 3D echocardiography and tissue Doppler
maging, Minnesota Living with Heart Failure
uestionnaire (MLWHFQ), 6-min hall walk test
6MHW) and 24-h Holter monitor. Patients who
et the inclusion criteria were implanted with an
ptimizer III System (IMPULSE Dynamics, Inc.).
etails of the System implant have been provided
reviously (12). In brief, 2 right ventricular elec-
rodes were placed at the anterior and inferior septal
egions, respectively, for delivery of CCM, while a
ight atrial lead was placed at the right atrial
ppendage only for sensing the P-wave. Devices
ere programmed to deliver CCM signals 5 h per
ay (5 1-h periods distributed equally over the 24 h
f the day). Patients were seen in follow-up after 3
onths of CCM therapy, during which baseline
ests were repeated. The study protocol was ap-
roved by the ethics committee of the institution,
nd written informed consent was obtained from all
he patients.
chocardiography. Standard echocardiography with
oppler measurements was performed. Doppler
chocardiography was performed to assess LV dia-
tolic function by interrogation of transmitral and
ulmonary venous flow patterns. Left ventricular
iastolic function and cardiac output were assessed
y pulse-wave Doppler echocardiography (15). Dia-
tolic function was graded as normal, abnormal
elaxation, pseudonormal filling pattern, or restric-
ive filling pattern according to the established
riteria (16). The rate of systolic pressure rise
dP/dt) was estimated from the continuous-wave
oppler mitral regurgitation velocity curve (17).
yocardial performance index was also calculated
y dividing the sum of isovolumic contraction and
elaxation periods by the ejection period (18). Mi-B B R E V I A T I O N S
N D A C R O N YM S
CM cardiac contractility
odulation
RT cardiac resynchroniza
herapy
m peak early diastolic
elocity
F heart failure
V left ventricular
LWHFQMinnesota Livin
ith Heart Failure Questionn
m peak systolic velocity
e-SD standard deviation
he time to peak myocardial
arly diastolic velocity
s-SD standard deviationral regurgitation was quantified by the area of the
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1343egurgitant jet measured by color Doppler expressed
s a percentage of left atrial area in the apical
-chamber view; the average of the results of at least
consecutive beats in sinus rhythm was taken for
his parameter. The doctors who performed echo-
ardiographic examinations were unaware of the
reatment status of CCM. Furthermore, as CCM
as delivered intermittently (5 h/day), the
ollow-up echocardiography was performed at the
ime of no active CCM signals delivered in order to
aintain the blinding of image acquisition.
eal-time 3D echocardiography. Real-time 3D echo-
ardiography was performed in the apical 4-chamber
iew by acquiring pyramidal full-volume images
f the LV with a matrix-array transducer (X3-1,
.9/3.8 MHz, iE33, Philips, Andover, Massa-
husetts). The image was adjusted to optimize
he orthogonal 2D and then 3D image qualities
ith modified gain settings and compression
ontrols as well as depth and lateral gain compen-
ation to optimize full-volume acquisition. Patients
ere instructed to hold their breath to minimize
rtifacts induced by breathing during full-volume
cquisition, which was triggered to the R-wave on
he electrocardiogram (ECG) of every cardiac cycle,
esulting in a total acquisition time of 4 heart beats.
V full-volume images with clear endocardial bor-
ers were stored digitally and transferred to a work
tation for offline analysis (19–24). Quantitative
nalysis of 3D echocardiography images were per-
ormed offline in a blinded fashion by dedicated
oftware (Q-Lab 6.0, Philips). In our echocardio-
raphic core laboratory, blinding of data was main-
ained by scrambling echocardiographic examina-
ions of all the time points for all the patients in a
andom order. Also, doctors who analyzed echocar-
iographic data were not involved in clinical man-
gement or follow-up of the patients, and therefore,
hey were totally unaware of the treatment status.
uring offline analysis, from the automatically cut
lanes that consisted of nonforeshortened end-
iastolic apical 2- and 4-chamber views, 5 anatomic
oints were manually defined that included 2 points
o identify the mitral valve annulus in each of the 2
pical views and 1 point to identify the apex in
ither view. A detection procedure was followed by
he automated software to trace the LV endocardial
order according to the preset mathematical model.
he same procedure was repeated in the end-
ystolic frame. The surface detection could be ed-
ted manually if tracings were suboptimal. Thus,
ime-volume curves were derived from regional
olumetric data of 17 myocardial segments accord-ng to American Society of Echocardiography clas-
ification (6 basal, 6 middle, and 5 apical segments),
nd from which the LV end-diastolic and -systolic
olumes and ejection fraction were derived. Inter-
bserver and intraobserver variability for measure-
ent of LV ejection fraction was assessed in 15
andomly selected patients; these were 6.7% and
.0%, respectively.
issue Doppler imaging. Color-coded tissue Dopp-
er imaging was performed from the 3 standard
pical views (apical 4-, 2-, and 3-chamber views) to
ssess LV long-axis function (Vivid 7, Vingmed-
eneral Electric, Horten, Norway) as previously
escribed (25). Images were optimized for pulse
Table 1. Baseline Clinical Characteristics of Patients Who
Received CCM (n  30)
Age (yrs) 60 11
Sex
Male 80%
Female 20%
Etiology
Ischemic 50%
Nonischemic 50%
NYHA functional class III 100%
QRS duration (ms) 99 15
LV ejection fraction (%) 29.0 6.5
VO2 max (ml/kg/min) 15.9 4.7
ICD 6.7%
Diuretics 66.7%
ACEI or ARB 83.3%
Beta-blocker 73.3%
Aldactone 13.3%
Digoxin 6.7%
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin II
receptor blocker; CCM  cardiac contractility modulation; ICD  implantable
cardioverter-deﬁbrillator; LV  left ventricular; NYHA  New York Heart
Association; VO2 max  maximal oxygen consumption.
Table 2. Comparison of Clinical Status Before and 3 Months Aft
Baseline 3 Mo
Heart rate (beats/min) 77 15 74
24-h PVC 1,259 2,109 1,440
Systolic blood pressure (mm Hg) 120 22 122
Diastolic blood pressure (mm Hg) 75 13 75
NYHA functional class (% patients)
II — 8
III 100 1
MLWHF quality of life score 23 19 20
6-min hall walk (m) 331 85 358
VO2 max (ml/kg/min) 15.9 4.7 14.3
Maximal exercise (METs) 4.5 1.4 4.0
METmetabolic equivalent; MLWHFMinnesota Living With Heart Failure; PVCer CCM Therapy
nths p Value
12 0.257
1,522 0.337
23 0.594
15 0.881
3 0.001
7
18 0.577
83 0.015
4.6 0.059
1.3 0.060
 premature ventricular
contraction; other abbreviations as in Table 1.
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1344epetition frequency, color saturation, and sector
ize and depth to achieve the highest possible frame
ate of 100 Hz. At least 5 consecutive beats were
tored, and the images were analyzed offline with
he aid of a customized software package (EchoPac
C SW-only, version 6.1.1, Vingmed-General
lectric). Myocardial velocity curves were reconsti-
uted offline using the 6-basal and 6-mid segmental
odel, which consisted of septal, lateral, anterosep-
al, posterior, anterior, and inferior segments at
oth basal and mid-levels in the left ventricle
25,26). The basal segments were sampled just
bove the mitral annulus level, and the middle
egments were sampled at the mid-level of the LV.
arkers with valve opening and closing events
ould appear on the ECG recordings during offline
nalysis. To assess regional systolic function, the
of Global LV Function Before and 3 Months After CCM Therapy
Baseline 3 Months p Value
(%) 29.0 6.5 33.1 6.5 0.001
me (ml) 115 35 103 37 0.001
me (ml) 159 40 150 40 0.002
ricity index 1.77 0.24 1.88 0.30 0.008
ericity index 1.66 0.20 1.72 0.21 0.015
in) 2.9 1.1 3.3 1.0 0.03
(% LA area) 22 14 17 15 0.032
s) 736 112 882 128 0.010
0.72 0.26 0.62 0.16 0.01
2.5 0.6 3.0 0.7 0.001
2.2 0.6 2.5 0.7 0.001
s) 0.68 0.27 0.64 0.25 0.383
s) 0.61 0.26 0.65 0.26 0.248
1.6 1.5 1.6 1.7 0.733
403 125 417 107 0.403
integral (cm) 13.8 3.5 14.7 3.7 0.04
patients)
on pattern 30 40 0.014
ng pattern 27 37
attern 43 23
locity (cm/s) 3.5 1.1 3.8 1.3 0.067
21.2 11.7 18.3 10.0 0.043
3.3 1.5 3.3 1.3 0.910
2.9 1.3 2.9 1.1 0.827
3.1 1.5 3.5 1.6 0.013
2.6 1.2 2.9 1.3 0.005
late diastolic velocity of the 6 basal LV segments; Am-12  mean myocardial
e 6 basal, 6 mid LV segments; dP/dt  rate of systolic pressure rise; Em-6 
stolic velocity of the 6 basal LV segments; Em-12  mean myocardial early
asal, 6 mid LV segments; E=myocardial early diastolic velocity at septal mitral
PI  myocardial performance index; Sm-6  mean myocardial systolic velocity
; Sm-12  mean myocardial systolic velocity of the 6 basal, 6 mid LV segments;nal; other abbreviations as in Table 1.eak systolic velocities during the ejection phase
Sm) of individual segments were measured, and
lobal LV systolic function was defined as the mean
f the 6 basal and 12 LV segmental Sm values
Mean Sm-6 and Mean Sm-12, respectively). Sim-
larly, regional diastolic function was measured as
he peak early diastolic velocity (Em) of each
ndividual segment, and global LV diastolic func-
ion was defined by the mean 6 basal and 12 LV
egmental Em values (Mean Em-6 and Mean
m-12, respectively).
To assess systolic dyssynchrony, we calculated the
tandard deviation of the time to peak myocardial
ystolic velocity during ejection phase of all the 12
V segments (Ts-SD). Also, the maximal delay in
s was presented in each of the 3 apical views. For
iastolic dyssynchrony, the standard deviation of
he time to peak myocardial early diastolic velocity
f the 12 LV segments (Te-SD) was calculated.
hese time domain variables were measured relative
o the timing of the QRS complex (25,27). The
nterobserver and intraobserver variabilities for
easuring dyssynchrony were compared in 60 con-
ecutive measurements and were found to be 4.7%
nd 3.2%, respectively (26).
tatistics. Data were analyzed using a statistical
oftware program (SPSS for Windows, version
3.0.1, SPSS Inc., Chicago, Illinois). Paired sample
test or Wilcoxon matched-pairs signed rank test
as used when appropriate for comparisons of
ontinuous or categorical variables between baseline
nd follow-up. Linear regression was employed to
nvestigate the correlation between pairs of para-
etric variables. Comparison of nonparametric data
as performed by Pearson chi-square test. The
esults were expressed as mean  SD. A p value of
0.05 was considered statistically significant.
E S U L T S
atient baseline characteristics are summarized in
able 1. The mean QRS duration was 99  15 ms.
bout one-half of patients had ischemic etiology of
F. The mean LV ejection fraction was 29.0 6.5%.
linical assessment of CCM therapy. There was sig-
ificant improvement of NYHA functional class
fter 3 months of CCM treatment, with an average
ecrease of almost 1 class (Table 2). The 6MHW
istance also increased significantly by an average of
early 30 m. However, the improvement of the
LWHFQ score was not significant. The 24-h
olter monitoring showed that there was no sig-Table 3. Comparison
by Echocardiography
Systolic function
LV ejection fraction
LV end-systolic volu
LV end-diastolic volu
LV end-systolic sphe
LV end-diastolic sph
Cardiac output (ml/m
Mitral regurgitation
LV dP/dt (mm Hg/
MPI
Mean Sm-6 (cm/s)
Mean Sm-12 (cm/s)
Diastolic function
Mitral E velocity (m/
Mitral A velocity (m/
Mitral E/A ratio
LV ﬁlling time (ms)
Mitral velocity time
LV ﬁlling pattern (%
Abnormal relaxati
Pseudonormal ﬁlli
Restrictive ﬁlling p
Septal annulus E= ve
E/E=
Mean Em-6 (cm/s)
Mean Em-12 (cm/s)
Mean Am-6 (cm/s)
Mean Am-12 (cm/s)
Am-6  mean myocardial
late diastolic velocity of th
mean myocardial early dia
diastolic velocity of the 6 b
annulus; LA  left atrial; M
of the 6 basal LV segmentsificant change in the number of premature ven-
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1345ricular contractions after CCM, indicating no pro-
rrhythmic effect.
lobal assessment of LV function and reverse remod-
ling. Using real-time 3D echocardiography, there
as significant reduction of LV end-systolic volume
ith an average of 11.5  10.5% (p  0.001)
Table 3) (Figs. 1A and 1B). The LV end-diastolic
olume was also reduced by 5.5  8.0% (p 
.002), and LV ejection fraction increased by 4.8 
.6% (absolute percentage point increase) (p 
.001). Improvement of LV systolic function was
orroborated by tissue Doppler imaging, which
howed a significant increase in the mean Sm value of
he 6 basal LV segments (p 0.001) (Figs. 2A to 2F)
nd mean Sm value of the 12 LV segments (p 
.001), which are markers for global LV systolic
unction. There was also improvement of cardiac
utput (p  0.03), dP/dt (p  0.01), and myocar-
ial performance index (p  0.01). Other parameters
hat were improved after CCM included sphericity
ndex (p  0.008) and mitral regurgitation (p 
.032) (Table 3).
Doppler assessment of diastolic function did not
eveal significant changes of conventional indices,
ncluding E velocity, A velocity, and E/A ratio
Table 3). However, LV diastolic pressure was
educed after CCM as reflected by the reduction of
/E= ratio (p  0.043). This was also supported by
he lower prevalence of restrictive filling pattern
fter CCM (Z  2.460, p  0.014). However,
issue Doppler imaging revealed that early diastolic
unction remained unchanged as reflected by the
ean 6 basal and 12 LV segment Em values (Table
, Figs. 2A to 2F).
ssessment of regional LV function and systolic
yssynchrony. Tissue Doppler imaging assessment
f regional systolic function, i.e., Sm, was per-
ormed at the basal segments of all the 6 LV walls.
his included septal and lateral walls in the
-chamber view, anterior and inferior walls in the
-chamber view, as well as anterior-septal and
osterior walls in the 3-chamber view. As shown in
able 4, there were significant increases in Sm of all
he LV walls (all p  0.05), with a statistically
onsignificant trend for improvement in the septal
all (p  0.06).
In contrast to the uniform improvement of re-
ional systolic function, regional assessment of early
iastolic function by tissue Doppler imaging (i.e.,
m) did not show any evidence of increase after
CM (Table 4).
At baseline, 8 patients (27%) had significant LVyssynchrony by Ts-SD measurement, and this fappened in 9 patients (30%) at 3-month follow-
p. In addition, there were no changes in Ts-SD
nd other indices of systolic dyssynchrony, includ-
ng opposite wall delay between baseline and
-month follow-up (all p  0.05). Similarly, index
f diastolic dyssynchrony (i.e., Te-SD) was un-
hanged throughout the study period.
I S C U S S I O N
n patients receiving treatment with CCM for 3
onths, there was improvement of LV systolic
unction as evidenced by an increase in ejection
raction measured using real-time 3D echocardiog-
aphy and systolic contractility by tissue Doppler
maging, which resulted in LV reverse remodeling.
hese favorable changes were related to augmenta-
ion of systolic function uniformly in all regions
f the LV, not just limited to the septal wall
here CCM signals were delivered. Furthermore,
itral regurgitation was reduced. LV diastolic
Figure 1. LV Reverse Remodeling After CCM
Cropped 3-dimensional echocardiographic image at end-systolic fra
after (B) cardiac contractility modulation (CCM) therapy in a patient
was achieved with reduction in left ventricular (LV) end-systolic vol
86 ml) and gain in ejection fraction (27.3% vs. 37.5%).me before (A) and
. Reverse remodeling
ume (145 ml vs.unction was unaffected by CCM, and there was
n
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1346o evidence that CCM impacted on systolic or
iastolic dyssynchrony.
mprovement of LV systolic function and LV reverse
emodeling after CCM. Despite recent studies that
eported improvement of symptoms and exercise
apacity, whether CCM would induce favorable
hanges in cardiac structure and function was
argely unknown. Results of multicenter trials have
een mixed (10,11); however, the accuracy of
-mode measurement of dilated ventricles and
ith regional wall dyskinesia (e.g., in coronary heart
isease) introduces a lot of variability, and results
CM on Systolic versus Diastolic Function
g of apical 4-chamber (A and B), 2-chamber (C and D), and 3-chamb
cardiac contractility modulation (CCM) therapy in the same patient a
arrows) of the 6 basal segments was improved (3.0 cm/s vs. 3.9 cm/s
.5 cm/s).ave therefore been questioned. Real-time 3D 3chocardiography has been validated to be highly
ccurate and reproducible in assessing LV volume
nd ejection fraction, with values reflecting true
easurements when compared with cardiac mag-
etic resonance and CT scan (14). Furthermore,
eal-time 3D echocardiography is much more ac-
urate than 2D echocardiography and far superior
o M-mode methods for such purposes. Our study
mployed real-time 3D echocardiography and re-
orted an absolute gain in ejection fraction of 4.8
.6%, whereas LV end-systolic volume reduced by
1.5  10.5% following treatment with CCM after
and F) views showing myocardial velocities before (A, C, and E)
Figure 1. At 3 months, the mean value of the peak myocardial
hereas that of the peak early diastolic velocity (Em) (arrowheads)Figure 2. Impact of C
Tissue Doppler imagin er (E
and after (B, D, and F) s in
systolic velocity (Sm) ( ), wmonths.
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1347In this study, we made use of tissue Doppler
maging to assess long-axis systolic function by
easuring Sm, which had been previously validated
s a marker of LV contractility. Therefore, the
ncrease of the averaged Sm in both 6 basal seg-
ents and 12 LV segments confirmed that the
herapeutic effect of CCM was conveyed by en-
ancing LV intrinsic contractility. As a result, it
ould augment coaptation of the mitral valve and
herefore decrease the amount of mitral regurgita-
ion. As a consequence of better forward ejection of
lood, the volume unloading effect and the allevia-
ion of mitral regurgitation, LV reverse remodeling,
nd reduction of LV filling pressure were observed.
he latter was confirmed by the observed reduction
f E/E=.
egional systolic versus diastolic function andmechanical
ynchrony after CCM. Mechanistic studies will pro-
ide insight into how CCM improves LV function.
e observed that CCM did not just augment
ontractility at the septal and adjacent walls where
he 2 electrodes were placed; rather, systolic func-
ion was enhanced in the entire LV including the
ree-wall segments. Therefore, in the long run, the
oncerted force in all 6 regions of the LV would
ontribute to the improvement of LV global systolic
unction, resulting in LV reverse remodeling and
eduction of mitral regurgitation. These findings
re completely consistent with a recent report con-
erning CCM-induced reverse molecular remodel-
ng (8). When HF was experimentally induced in
nimals, there was a switch in expression of a host
f genes from a normal adult genotype to a fetal
enotype indicative of myocardial pathology. In
uch animals, Imai et al. (8) showed that within
ours of initiating CCM signal delivery, there was
reversion back towards a normal genotype only in
he region of the heart where signals were delivered.
owever, following 3 months of therapy, gene
xpression improved locally as well as in regions
emote from the site of signal delivery (8). This
rior finding, combined with the present findings of
mproved performance in all regions of the heart,
ndicates that although signal delivery is local,
lobal benefits are achieved in the long run.
Three additional interesting findings were ob-
erved in the current study. First, there was no
vidence of pro-arrhythmic effect of CCM as our
atients showed a trend for the number of prema-
ure ventricular contractions observed during 24-h
olter monitoring to decrease following the
-month treatment period. Second, despite im-
rovement of global LV systolic function, CCM pxerted no direct effect on active diastolic function.
espite the fact that early diastolic function is an
nergy-consuming process that involves the re-
ptake of intracellular calcium in addition to the
assive recoil, CCM does not appear to play a role
n modulating ventricular diastolic function. Third,
he augmentation of global LV function was not
xplained by changes in mechanical synchrony since
either systolic nor diastolic synchrony was changed
y CCM, though the prevalence of LV dyssyn-
hrony was relatively low in these patients at base-
ine. This further supports the notion that the
mproved global function is likely a result of im-
roved myocyte systolic function. This is in contrast
o CRT in which the improvement of systolic
unction is largely related to the alleviation of
ystolic dyssynchrony (27). Thus, because the
echanisms are completely different, the effects of
CM can be additive to those of CRT, as shown
Table 4. Improvement in Regional Myocardial Contraction But N
CCM Therapy Deﬁned by Tissue Doppler Imaging
Baseline 3
Systolic function
Sm, basal septal (cm/s) 2.8 0.9
Sm, basal lateral (cm/s) 2.4 1.0
Sm, basal anterior (cm/s) 2.3 0.9
Sm, basal inferior (cm/s) 2.9 0.9
Sm, basal anteroseptal (cm/s) 2.2 0.9
Sm, basal posterior (cm/s) 2.5 0.9
Diastolic function
Em, basal septal (cm/s) 3.4 1.9
Em, basal lateral (cm/s) 3.5 2.1
Em, basal anterior (cm/s) 3.3 2.0
Em, basal inferior (cm/s) 3.4 1.5
Em, basal anteroseptal (cm/s) 2.5 1.4
Em, basal posterior (cm/s) 3.7 2.3
Am, basal septal (cm/s) 3.6 1.9
Am, basal lateral (cm/s) 2.4 1.6
Am, basal anterior (cm/s) 2.7 1.7
Am, basal inferior (cm/s) 3.9 2.0
Am, basal anteroseptal (cm/s) 2.9 1.5
Am, basal posterior (cm/s) 3.0 1.6
Dyssynchrony
Ts-SD (ms) 28.2 11.2 2
Septal to lateral wall delay in Ts (ms) 47.9 29.2 4
Anterior to inferior wall delay in Ts (ms) 45.2 27.0 4
Anteroseptal to posterior wall delay in Ts (ms) 36.2 34.2 3
Te-SD (ms) 30.0 18.3 3
Am  myocardial late diastolic velocity at the time of atrial contraction; Em 
velocity; Sm  myocardial systolic velocity; Te-SD  standard deviation of the
early diastolic velocity of the 12 left ventricular segments; Ts-SD  the standard
peak myocardial systolic velocity of the 12 left ventricular segments; Ts time to
velocity; other abbreviations as in Table 1.ot Relaxation After
Months p Value
3.1 0.9 0.064
2.9 1.1 0.005
2.8 1.1 0.024
3.3 0.9 0.001
2.8 0.8 0.001
3.0 1.0 0.001
3.1 1.6 0.219
3.6 2.3 0.815
3.5 1.7 0.559
3.5 1.5 0.570
2.8 1.5 0.191
3.2 1.7 0.059
3.9 2.1 0.152
2.7 1.6 0.105
3.3 1.6 0.015
4.3 2.0 0.140
3.2 1.7 0.050
3.2 1.7 0.369
7.9 12.7 0.809
6.1 32.0 0.741
3.5 28.7 0.645
5.5 38.7 0.908
0.1 20.7 0.943
myocardial early diastolic
time to peak myocardial
deviation of the time to
peak myocardial systolicreviously (7,28). Finally, this finding also addresses
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1348oncerns that local application of CCM places
ndue stress on myocardium remote from the site of
ignal delivery, which could actually have the po-
ential to adversely affect function in those areas (6);
his was evidently not the case.
The clinical improvement of symptoms and ex-
rcise capacity in our study was comparable to those
bserved in previous multicenter trials (10). How-
ver, this was not the focus of the present study,
ince it was a small, unblinded study in which
easures of patient symptoms and exercise toler-
nce were subject to placebo effect. This might also
ave explained the lack of improvement in quality
f life assessment in the present study. Of note, the
ean MLWHFQ score of our patients was rela-
ively low, which rendered further improvement
fter CCM a technical challenge.
One limitation of the present study is the relatively
hort duration (3 months) of follow-up. Results of 1
rior clinical trial suggests that the clinical effect of
CM builds over time (10), so it might be expected
hat even more significant effects could be observed
ver longer periods of follow-up. Also, our study did
ot include a control group for comparison. However,electric currents applied during the non-excitatory, caeceived CRT, such as in the CARE-HF (Cardiac
esynchronization in Heart Failure) study (29), no
hanges in LV volume and ejection fraction would
ave been expected after follow-up for 3 months.
urthermore, the blinding of data acquisition and
ffline analysis would have minimized the bias during
nterpretation of echocardiographic results.
O N C L U S I O N S
hree months of treatment with CCM signals im-
roved global LV systolic function by means of aug-
enting intrinsic contractility in all regions of the LV,
esulting in reverse remodeling and reduction of mitral
egurgitation. On the other hand, CCM did not affect
lobal or regional LV diastolic function, and it had no
mpact on the degree of synchrony of myocardial
ontraction. Additional studies are underway to assess
he long-term clinical impact of CCM.
eprint requests and correspondence: Dr. Prof. Cheuk-
an Yu, Institute of Vascular Medicine and Division of
ardiology, Department of Medicine and Therapeutics,
rince of Wales Hospital, The Chinese University of
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